HC Wainwright Analysts Decrease Earnings Estimates for ZNTL

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Research analysts at HC Wainwright reduced their Q1 2025 earnings estimates for shares of Zentalis Pharmaceuticals in a research note issued to investors on Thursday, March 27th. HC Wainwright analyst A. Fein now expects that the company will earn ($0.52) per share for the quarter, down from their previous forecast of ($0.41). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($2.11) EPS, FY2026 earnings at ($2.56) EPS, FY2027 earnings at ($2.61) EPS, FY2028 earnings at ($1.96) EPS and FY2029 earnings at ($0.99) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.09. The firm had revenue of $26.90 million during the quarter.

A number of other equities research analysts have also weighed in on the company. UBS Group lowered their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Wells Fargo & Company decreased their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Finally, Wedbush reiterated a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, March 28th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $8.24.

Zentalis Pharmaceuticals Stock Down 12.6 %

Shares of Zentalis Pharmaceuticals stock opened at $1.39 on Monday. The firm has a market cap of $99.82 million, a price-to-earnings ratio of -0.56 and a beta of 1.75. Zentalis Pharmaceuticals has a 52-week low of $1.36 and a 52-week high of $16.21. The company’s 50-day simple moving average is $2.01 and its 200-day simple moving average is $2.83.

Insider Transactions at Zentalis Pharmaceuticals

In related news, Director Jan Skvarka acquired 60,000 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the transaction, the director now owns 149,551 shares in the company, valued at $257,227.72. This trade represents a 67.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Ingmar Bruns bought 20,000 shares of Zentalis Pharmaceuticals stock in a transaction on Thursday, February 6th. The stock was purchased at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the completion of the acquisition, the insider now owns 36,629 shares in the company, valued at $83,514.12. This represents a 120.27 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of institutional investors have recently modified their holdings of ZNTL. Wealth Enhancement Advisory Services LLC boosted its position in Zentalis Pharmaceuticals by 194.7% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 200,113 shares of the company’s stock worth $606,000 after acquiring an additional 132,220 shares during the last quarter. Vident Advisory LLC acquired a new position in Zentalis Pharmaceuticals in the fourth quarter valued at $45,000. State of Wyoming lifted its position in Zentalis Pharmaceuticals by 124.6% during the fourth quarter. State of Wyoming now owns 34,716 shares of the company’s stock worth $105,000 after buying an additional 19,262 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Zentalis Pharmaceuticals in the 4th quarter worth about $52,000. Finally, Nuveen Asset Management LLC grew its holdings in Zentalis Pharmaceuticals by 35.2% in the 4th quarter. Nuveen Asset Management LLC now owns 641,407 shares of the company’s stock valued at $1,943,000 after buying an additional 167,062 shares during the period.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.